Search results: Sage Journals

Free accessCase reportFirst published January, 2024

Niraparib-induced pure red cell aplasia

Kadriye Bir Yücel, Seyma Yıldız, Osman Sütcüoglu [...]

Journal of Oncology Pharmacy Practice

Restricted accessCase reportFirst published October, 2019

Niraparib – A promising drug with hematological toxicity

Naga SK Patibandla, Dulabh K Monga

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2022

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published September, 2017

Niraparib in ovarian cancer: results to date and clinical potential

Davide Caruso, Anselmo Papa, Silverio Tomao [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2019

Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

Carlo Lazzaro, Nicola Amedeo Mazzanti, Fabio Parazzini

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Open accessResearch articleFirst published 2024

Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with BRCA wild-type recurrent ovarian cancer

Robert L. Coleman, Jessica A. Perhanidis, Linda Kalilani [...]

Therapeutic Advances in Medical Oncology

Open accessCase reportFirst published September, 2023

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature

Roger K. C. Ngan

Journal of International Medical Research

Restricted accessResearch articleFirst published February, 2025

Whole-Exome Sequencing Identifies Germline BLM Mutation in Ovarian Hepatoid Adenocarcinoma with Favorable Response to Niraparib and Anlotinib Combination Therapy—A Case Report and Literature Review

Xiaofang Zhang, Lian Xu, Yidan Cao [...]

International Journal of Surgical Pathology

Restricted accessReview articleFirst published October, 2020

Niraparib for the Treatment of Recurrent Epithelial Ovarian,Fallopian Tube,or Primary Peritoneal Cancer

Lloreta Kerliu, Samantha Myruski, Afeefa Bhatti [...]

Annals of Pharmacotherapy

Restricted accessResearch articleFirst published June, 2025

Efficacy and safety of niraparib in platinum-sensitive recurrent ovarian cancer: retrospective observational study in a tertiary hospital

Elena Prado-Mel, Paloma Suárez-Casillas, Lupe Rodríguez-de Francisco [...]

Journal of Oncology Pharmacy Practice

Free accessCase reportFirst published January, 2024

Niraparib-induced pure red cell aplasia

Kadriye Bir Yücel, Seyma Yıldız, Osman Sütcüoglu [...]

Journal of Oncology Pharmacy Practice

Restricted accessCase reportFirst published October, 2019

Niraparib – A promising drug with hematological toxicity

Naga SK Patibandla, Dulabh K Monga

Journal of Oncology Pharmacy Practice

Open accessResearch articleFirst published 2022

Quality-adjusted time without symptoms of disease or toxicity and quality-adjusted progression-free survival with niraparib maintenance in first-line ovarian cancer in the PRIMA trial

Maria-Pilar Barretina-Ginesta, Bradley J. Monk, Sileny Han [...]

Therapeutic Advances in Medical Oncology

Open accessReview articleFirst published September, 2017

Niraparib in ovarian cancer: results to date and clinical potential

Davide Caruso, Anselmo Papa, Silverio Tomao [...]

Therapeutic Advances in Medical Oncology

Open accessResearch articleFirst published 2019

Severe haematological toxicities in relapsed ovarian cancer treated with olaparib or niraparib: an Italian cost-minimization analysis

Carlo Lazzaro, Nicola Amedeo Mazzanti, Fabio Parazzini

Global & Regional Health Technology Assessment: Italian;Northern Europe and Spanish

Open accessResearch articleFirst published 2024

Real-world overall survival in second-line maintenance niraparib monotherapy versus active surveillance in patients with BRCA wild-type recurrent ovarian cancer

Robert L. Coleman, Jessica A. Perhanidis, Linda Kalilani [...]

Therapeutic Advances in Medical Oncology

Open accessCase reportFirst published September, 2023

First-line maintenance therapy with niraparib in advanced platinum-sensitive ovarian cancer: two ‘long responder’ case reports and review of the current literature

Roger K. C. Ngan

Journal of International Medical Research

Restricted accessResearch articleFirst published February, 2025

Whole-Exome Sequencing Identifies Germline BLM Mutation in Ovarian Hepatoid Adenocarcinoma with Favorable Response to Niraparib and Anlotinib Combination Therapy—A Case Report and Literature Review

Xiaofang Zhang, Lian Xu, Yidan Cao [...]

International Journal of Surgical Pathology

Restricted accessReview articleFirst published October, 2020

Niraparib for the Treatment of Recurrent Epithelial Ovarian,Fallopian Tube,or Primary Peritoneal Cancer

Lloreta Kerliu, Samantha Myruski, Afeefa Bhatti [...]

Annals of Pharmacotherapy

Restricted accessResearch articleFirst published June, 2025

Efficacy and safety of niraparib in platinum-sensitive recurrent ovarian cancer: retrospective observational study in a tertiary hospital

Elena Prado-Mel, Paloma Suárez-Casillas, Lupe Rodríguez-de Francisco [...]

Journal of Oncology Pharmacy Practice